Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT with Chemo-Immunotherapy in ES-SCLC
NCT04923776Phase 2Terminated
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial. Primary endpoint: Progression Free Survival Rate at 6 months. Started Sep 2021; status: terminated.
Beyond the preview
Go deeper on NCT04923776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04923776.